Androgenic alopecia. Androgenic alopecia
Conditions
Interventions
Intervention 1: Intervention group: Subcutaneous injection of the solution containing growth factors obtained from the human placenta is performed in 15 patients with androgenic alopecia. Placental gr
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with androgenetic alopecia Age 18 to 50 years Male Norwood-Hamilton grade II to V
Exclusion criteria
Exclusion criteria: Patients with two or more diagnoses of hair loss Treatment of hair loss in the last 3 months Patients undergoing radiotherapy and chemotherapy Immunosuppressive drugs or corticosteroids during the previous 4 weeks Uncontrolled chronic diseases Malignancy Coagulopathy or the use of anticoagulants History of autoimmune diseases HBV, HCV and HIV infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Injection day, and 2 weeks, 1, 2, 4 and 6 months after first injection. Method of measurement: History and clinical examination based on Common Terminology Criteria for Adverse Events criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Frontal and vertex hair density. Timepoint: 1, 2, 4, and 6 months after the first injection. Method of measurement: Digital videotrichoscopy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Bajouri
Tehran University of Medical Sciences
Outcome results
None listed